Effects of Alpha-GPC on Muscle Power, GH Levels, and Cognitive Function
NCT06690619, Not applicable, Completed, Lindenwood University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effects of Alpha-GPC on Muscle Power, GH Levels, and Cognitive Function | ClinicalTrials.gov |
| NCT number | NCT06690619 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 20 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Lindenwood University | ClinicalTrials.gov |
| Conditions | Cognition - Other, Strength Outcomes | ClinicalTrials.gov |
| Interventions | Placebo, 315 mg Alpha-GPC, 630 mg Alpha-GPC | ClinicalTrials.gov |
| First posted | 2024-11-15 | ClinicalTrials.gov |
| Last updated | 2024-11-15 | ClinicalTrials.gov |
Registered outcomes 14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Cognitive Performance-NBack | Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during visits 2, 3, and 4 | The N Back cognitive performance test (https://www.lumosity.com/app/v4/games/speed-match-overdrive-web ) | ClinicalTrials.gov |
| Primary | Cognitive Performance | Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during visits 2, 3, and 4 | Flanker Cognitive Performance Test (https://www.psytoolkit.org/experiment-library/flanker.html) | ClinicalTrials.gov |
| Primary | Cognitive Performance | Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during visits 2, 3, and 4 | Stroop Color Matching Test | ClinicalTrials.gov |
| Secondary | Lower Body Power | Assessed 90 minutes post-ingestion during each study visit | Vertical Jump for Lower Body Power (Tendo) | ClinicalTrials.gov |
| Secondary | Upper Body Power | Assessed 90 minutes post-ingestion during each study visit | Bench Press Throw for Upper Body Power (Tendo) @ 50%1RM | ClinicalTrials.gov |
| Secondary | Growth Hormone | Assessed before exercise and 5, 15, 30, and 60 minutes after exercise during visits 2, 3, and 4 | Serum Growth Hormone Concentrations | ClinicalTrials.gov |
| Secondary | Perceived mood assessed using visual analog scale | Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during visits 2, 3, and 4 | Perceived mood assessed using the Visual Analog Scale (VAS), a 0-100 scale where 0 indicates 'worst mood imaginable' and 100 indicates 'best mood imaginable.' Higher scores represent better perceived mood. | ClinicalTrials.gov |
| Secondary | Perceived motivation assessment using visual analog scales | Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during visits 2, 3, and 4 | Perceived motivation assessed using the Visual Analog Scale (VAS), with a range of 0-100 where 0 indicates 'no motivation' and 100 indicates 'maximum motivation.' Higher scores represent better perceived motivation. | ClinicalTrials.gov |
| Secondary | Perceived Alertness Assessment Using Visual Analog Scale (VAS) | Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during visits 2, 3, and 4 | Perceived alertness assessed using the Visual Analog Scale (VAS), with a range of 0-100 where 0 indicates 'no alertness' and 100 indicates 'maximum alertness.' Higher scores represent better perceived alertness. | ClinicalTrials.gov |
| Secondary | Perceived Concentration Assessment Using Visual Analog Scale (VAS) | Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during visits 2, 3, and 4 | Perceived concentration assessed using the Visual Analog Scale (VAS), with a range of 0-100 where 0 indicates 'no concentration' and 100 indicates 'maximum concentration.' Higher scores represent better perceived concentration. | ClinicalTrials.gov |
| Secondary | Non-exertional Heart Rate Measurement | Assessed 60 minutes after ingestion of assigned test product and approximately 3.5 hours after ingestion during visits 2, 3, and 4 | Heart rate measured in a non-exertional state using an automated sphygmomanometer. | ClinicalTrials.gov |
| Secondary | Non-exertional Blood Pressure Measurement (Systolic and Diastolic) | Assessed 60 minutes after ingestion of assigned test product and approximately 3.5 hours after ingestion during visits 2, 3, and 4 | Blood pressure measured in a non-exertional state using an automated sphygmomanometer. Both systolic and diastolic pressures will be assessed. | ClinicalTrials.gov |
| Other | Percent Body Fat | At baseline (Visit 1), at the start of the study. | Percent body fat assessed using bioelectrical impedance analysis | ClinicalTrials.gov |
| Other | Dietary Intake | Day 1, Day 8, and Day 15 | 24-Hour Dietary Intake using 24-hour recall approach. Energy and macronutrient intake were evaluated. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 39683633 | DERIVED | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| 1-Back Task | Primary outcome | ConductCognition |
| 2-Back Task | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)